12:00 AM
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

NeuroStar neurology data

An open-label, observational, U.S. study in 307 patients showed that NeuroStar TMS significantly improved self-reported quality of life as measured by EQ-5D scores from baseline to the end of the 5-week treatment period. Specifically, NeuroStar TMS led to improvements at week 5 vs. baseline in the proportion of patients...

Read the full 221 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >